Haemorrhagic diathesis develops in chronic renal failure, in which calcium antagonists are used widely as antihypertensive agents. Although calcium antagonists are reported to impair platelet function, it has not been examined whether calcium antagonists alter bleeding time. The present study was conducted to clarify whether calcium antagonists affect bleeding time in chronic renal failure. Patients with chronic renal failure without and with calcium antagonists were enrolled (n = 156), and bleeding time (Ivy's method) as well as blood parameters (BUN, creatinine, platelet counts, and haemoglobin) were compared in patients with normal and prolonged bleeding time. Among patients not taking calcium antagonists (n = 34), three cases manifested prolonged bleeding time, whereas abnormal bleeding time was observed in 31 patients out of 122. Positive correlations were observed between bleeding time and BUN in both calcium antagonist-untreated (r = 0.46) and -treated groups (r = 0.25). The odds ratio for pro-
Introduction
In advanced renal failure, bleeding diathesis is recognized as a complication leading to serious haemorrhagic events, including gastrointestinal bleeding and haemorrhagic pericardial effusion. Several lines of investigations have attempted to elucidate the mechanisms of bleeding tendency in chronic renal failure, and it has been documented that platelet function is impaired in uremic patients. 1, 2 Although the increasing incidence of bleeding complications as renal failure progresses suggests the uraemia-induced bleeding tendency, very few studies have been conducted examining the role of other factors in haemorrhagic diathesis in chronic renal failure. In chronic renal failure, systemic hypertension develops more frequently. In this circumstance, calcium antagonists are used longation of bleeding time in patients taking calcium antagonists was 3.52 (95% CI, 1.01-12.33). In 12 calcium antagonist-treated patients with prolonged bleeding time, the withdrawal of calcium antagonists markedly shortened bleeding time (from 11.3 ± 0.8 to 5.4 ± 0.8 min, P Ͻ 0.05, n = 12). In contrast, in the additional group (n = 9), the continued treatment with calcium antagonists had no effect on bleeding time (from 11.7 ± 0.9 to 10.0 ± 1.0 min). Despite the inhibitory effect of calcium antagonists on bleeding time, no clinically serious events associated with haemorrhagic diathesis developed. In conclusion, calcium antagonists prolong bleeding time in patients with chronic renal failure. The subclinical (laboratory) effect of calcium antagonists however is not necessarily associated with haemorrhagic events of clinical significance. widely, and are believed to be safe and effective in patients with chronic renal failure. Although the main action of calcium antagonists is to relax vascular smooth muscle, these agents exert additional action. Thus calcium antagonists are reported to inhibit platelet aggregation [3] [4] [5] [6] and elicit prolongation of bleeding time. 6 These observations suggest that when used in chronic renal failure, calcium antagonists might inhibit haemostatic mechanisms. The effect of calcium antagonists on haemostatic mechanisms in chronic renal failure however remains undetermined.
In the present study, we investigated the effects of calcium antagonists on bleeding time in the patients with advanced chronic renal failure. Furthermore, whether the effect of calcium antagonists on bleeding time was associated with haemorrhagic events of clinical significance was also assessed.
Patients and methods

Effect of calcium antagonists on bleeding time
One hundred and fifty-six patients with moderate to severe chronic renal failure, but not on haemo-dialysis were enrolled in this study. Most of the patients were admitted to our hospital for surgical construction of arterio-venous fistula, the management of hypertension, and the education of diet. These include the patients not taking (age 60 ± 3 years old; n = 34) and taking calcium antagonists (age 60 ± 1 years old; n = 122). Patients on antiplatelet therapy were excluded from the study. The information on clinical symptoms for haemorrhagic diathesis during the previous 3 months was obtained from all patients, and the laboratory examinations were conducted, including faecal occult blood test, ocular fundoscopy, cardiac ultrasound, and gastrointestinal endoscopy if required.
Bleeding time was evaluated by well-trained laboratory technicians with a modified Ivy method, using the Simplate II bleeding time device (normal range, 3-8 min). Blood urea nitrogen (BUN), serum creatinine, platelet counts and blood haemoglobin levels were evaluated as factors affecting bleeding time. BUN and serum creatinine were measured by autoanalyzer.
Effect of withdrawal of calcium antagonists on bleeding time
Among patients taking calcium antagonists, 21 patients were randomly assigned to two groups. In one group (n = 12), bleeding time was examined during the treatment with calcium antagonists and after the withdrawal of these agents, at an interval of 7-10 days. In the remaining group (n = 9), bleeding time was repeatedly evaluated at nearly the same interval during the continued use of calcium antagonists. The laboratory technicians who conducted bleeding time were not informed of whether calcium antagonists had been withdrawn or not. Informed consent was obtained from these patients.
Statistics
Results were expressed as the mean ± s.e.m. Statistical analysis was evaluated by two-way ANOVA followed by multiple comparison post hoc test. For 
Results
Effect of calcium antagonists on bleeding time Table 1 summarises patient profiles enrolled in this study (n = 156). Calcium antagonists were prescribed in a large proportion of cases (n = 122). Among the patients not taking calcium antagonists (n = 34), only three patients (ie, 8.8%) manifested prolonged bleeding time. In contrast, variable degrees of prolongation in bleeding time were observed in 25.4% of the patients treated with calcium antagonists. The odds ratio for prolongation of bleeding time in patients taking calcium antagonists was 3.52 (95% CI, 1.01-12.33).
In the patients not treated with calcium antagonists, BUN, serum creatinine, platelet counts, or haemoglobin, did not differ between the subgroup with normal bleeding time and that with prolonged bleeding time (Table 1) . Similarly, in patients treated with calcium antagonists, no differences were observed between these subgroups for any of the parameters examined. There was no gender difference in the development of prolonged bleeding time in any of the groups. Figure 1 summarises the relationship between bleeding time and other parameters including BUN, serum creatinine, platelet counts and haemoglobin in patients not taking calcium antagonists. Bleeding time was positively correlated with BUN (r = 0.46, P Ͻ 0.05). No correlations however were observed between bleeding time and serum creatinine or platelet counts. Blood haemoglobin levels were negatively correlated with bleeding time, with a correlation coefficient of 0.36 (P Ͻ 0.05).
In patients treated with calcium antagonists, a weak correlation was observed between bleeding time and BUN (r = 0.25, P Ͻ 0.05), whereas no corre- lations were noted between bleeding time and serum creatinine, platelet counts or haemoglobin (Figure 2 ). Of note, the regression line for the correlation between bleeding time and BUN in patients with calcium antagonists was shifted leftward, compared with that in patients without these agents (yintercept, 2.99 vs 1.27, P Ͻ 0.05); the slopes were not different between these lines (0.029 vs 0.036, P Ͼ 0.5).
The types of calcium antagonists used in this study were summarised in Table 2 . Although nifedipine and amlodipine were used more frequently, no predilection of calcium antagonists was noted with regard to the effect on bleeding time.
Despite the inhibitory action of calcium antagonists on bleeding time, the incidence of the events associated with bleeding tendency did not differ Figure 2 Correlation between bleeding time and blood urea nitrogen (BUN), creatinine, platelet counts, or haemoglobin in patients with chronic renal insufficiency taking calcium antagonists. Bleeding time was correlated with BUN (r = 0.25, P Ͻ 0.05, n = 122), but not creatinine, platelet counts, or haemoglobin. between the patients without calcium antagonists and those with calcium antagonists (Table 3) .
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Effect of withdrawal of calcium antagonists on bleeding time
Among 156 patients taking calcium antagonists, 21 patients with prolonged bleeding time were randomly assigned to two groups. In one group (BUN, 9.8 ± 1.1 mmol/l (58.7 ± 6.5 mg/dl); platelet, 18.8 ± 2.4 × 10 4 /mm 3 , n = 12], treatment with calcium antagonists was discontinued, and bleeding time was examined during the treatment with calcium antagonists and after cessation of these agents at an interval of 7 to 10 days. Thus, the withdrawal of calcium antagonists shortened bleeding time (from 11. 
Discussion
It is well established that patients with advanced chronic renal failure are at an increased risk for haematological complications. Although anaemia is a commonly observed complication, haemorrhagic events such as gastrointestinal bleeding and haemorrhagic pericardial effusion may ensue, and their incidence increases as renal function deteriorates. 7 It is traditionally believed that impaired renal function constitutes a central determinant of bleeding diathesis in chronic renal failure. Most of these patients however are on the antihypertensive therapy, of which calcium antagonists are the most widely prescribed in this circumstance. Despite several lines of studies reporting the inhibitory effect of calcium antagonists on platelet function, [3] [4] [5] [6] no investigations have been conducted examining the 
Figure 3
Changes in bleeding time after withdrawal of calcium antagonists in patients with chronic renal failure. The discontinuation of the treatment with calcium antagonists markedly shortened bleeding time (left, P Ͻ 0.05, n = 12). No changes were noted, however, when calcium antagonists were continued (right, n = 9). Ca-A, calcium antagonists.
role of calcium antagonists in the impaired haemostasis in chronic renal failure. The present study demonstrates that the number of patients with prolonged bleeding time is increased when calcium antagonists are given (odds ratio, 3.52). Furthermore, the withdrawal of calcium antagonists corrected the bleeding time (Figure 3 ). These findings clearly indicate that calcium antagonists affect bleeding time in patients on calcium antagonist therapy. It is traditionally believed that retention of uraemic toxins is responsible in large part for the haemorrhagic diathesis in chronic renal failure. 1 Horowitz et al 8, 9 demonstrated that accumulation of uraemic toxins including guanidinosuccinic acid is associated with impaired platelet aggregation and prolongation of bleeding time.
Indeed, the present study shows that bleeding time is prolonged as BUN elevates (Figure 1 ). In addition to the impaired haemostatic mechanism underlying chronic renal failure, calcium antagonists are reported to impair platelet aggregation, 3,4 prevent platelet adhesion, 10 and prolong bleeding time. 3 In the present study, during the treatment with calcium antagonists, the correlation between bleeding time and BUN is preserved, but shifted to lower BUN levels (Figure 2 ). Since hypertension is one of the most common complications in chronic renal failure, and end-stage renal failure favours the use of calcium antagonists rather than other antihypertensive agents (eg, ACE inhibitors), it is extremely important to evaluate the clinical relevance of the calcium antagonist in advanced chronic renal failure. We propose that the calcium antagonist augments the impaired nature of the haemostatic mechanism in advanced chronic renal failure.
Recently, it has been a matter of great interest that calcium antagonists affect haemostasis and vasomotor tone via mechanisms independent of the inhibition of voltage-dependent calcium channels. Thus, Takahara et al 3 reported that nifedipine inhibited platelet aggregation induced by ADP and collagen. Similarly, amlodipine prevented platelet adhesion. 10 In addition to these findings observed in vitro, the calcium antagonist is recently reported to increase nitric oxide from vascular endothelium. 11, 12 Additionally, Ding et al 13 have demonstrated that calcium antagonists enhance nitric oxide synthase expression in cultured endothelial cells. In this regard, Noris and Remuzzi 14 suggest that the accumulation of guanidinosuccinic acid, which stimulates endothelial nitric oxide production, 15, 16 is responsible for uraemic bleeding; the nitric oxide synthase inhibition normalised platelet dysfunction and bleeding time in uraemic rats. 17 It therefore is intriguing to speculate that calcium antagonists and the mechanism that underlies chronic renal failure act in concert to lengthen bleeding time via a common factor, ie, nitric oxide. Further investigations are required to determine this issue.
Of utmost importance, the present study indicates that the calcium antagonist does not cause clinically serious events associated with haemorrhagic diathesis. In this regard, Pahor et al 18 have recently demonstrated that calcium antagonists are associated with an increased risk of gastrointestinal haemorrhage in hypertensive patients over 67 years old. Our present findings, indicating the calcium antagonist-related prolongation of bleeding time, however do not necessarily support the clinical finding by Pahor et al 18 but rather may simply reflect the modulation of renal insufficiency-related bleeding tend-ency by calcium antagonists, since the regression line for the correlation between BUN and bleeding time is shifted leftward by calcium antagonists (Figures 1 and 2 ).
In conclusion, the present study demonstrates that the calcium antagonist is associated with prolonged bleeding time, which may modify the underlying haemostatic derangement observed in chronic renal failure. It requires large-scale investigations to determine whether the calcium antagonist elicits haemorrhagic events of clinical significance in chronic renal failure.
